Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Income from Continuing Operations (2023 - 2026)

Contineum Therapeutics' Income from Continuing Operations history spans 4 years, with the latest figure at 14399000.0 for Q1 2026.

  • Quarterly Income from Continuing Operations rose 9.21% to 14399000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 58352000.0 through Mar 2026, down 17.41% year-over-year, with the annual reading at 59813000.0 for FY2025, 41.54% down from the prior year.
  • Income from Continuing Operations came in at 14399000.0 for Q1 2026, up from 15105000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 41600000.0 in Q2 2023 to a low of 15873000.0 in Q2 2025.
  • The 4-year median for Income from Continuing Operations is 10267000.0 (2024), against an average of 7210153.85.
  • Year-over-year, Income from Continuing Operations plummeted 121.66% in 2024 and then grew 9.21% in 2026.
  • Contineum Therapeutics' Income from Continuing Operations stood at 7769000.0 in 2023, then crashed by 87.48% to 14565000.0 in 2024, then decreased by 3.71% to 15105000.0 in 2025, then rose by 4.67% to 14399000.0 in 2026.
  • Per Business Quant, the three most recent readings for CTNM's Income from Continuing Operations are 14399000.0 (Q1 2026), 15105000.0 (Q4 2025), and 12975000.0 (Q3 2025).